Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases

Savara Inc. has released a corporate presentation detailing its ongoing efforts to develop new therapies for rare respiratory diseases, with a primary focus on autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The presentation highlights the company’s lead investigational candidate, MOLBREEVI (molgramostim inhalation solution), which currently has conditional trade name acceptance from regulatory authorities but is not yet approved for any indication. Savara plans to resubmit a Biologics License Application (BLA) for MOLBREEVI in December 2025, following data that indicate a favorable benefit/risk profile and good tolerability. The presentation also provides insights into the patient journey, emphasizing the challenges of current treatment options such as whole lung lavage and the need for alternative therapies. The executive leadership team and their respective roles are outlined within the document. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here